Eleven years after Purdue Pharma LP pled guilty to marketing OxyContin as less addictive than other pain medicines the legal fallout has only intensified. Manufacturers and distributors are facing an ever-growing barrage of lawsuits and government prosecutors have launched new investigations of their sales and marketing practices. The expected settlements will not just have a financial impact on the firms involved, but may also set a precedent for what public health responsibilities companies are expected to bear.
OxyContin (oxycodone controlled-release) was approved by FDA in December 1995 as the first formulation of oxycodone that allowed dosing every...





